UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. 1. Name and Address of Reporting Person(s) IKENBERRY DR STANLEY O 20 W 9th Street MS 3-426 Kansas City, MO 64105 2. Issuer Name and Ticker or Trading Symbol Aquila, Inc. (ILAC) 3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary) 4. Statement for Month/Day/Year 09/30/2002 5. If Amendment, Date of Original (Month/Day/Year) 6. Relationship of Reporting Person(s) to Issuer (Check all applicable) [X] Director [ ] 10% Owner [ ] Officer (give title below) [ ] Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) [X] Form filed by One Reporting Person [ ] Form filed by More than One Reporting Person

~~FORM~~Table 4[I ]Non-Derivative ~~Check~~Securities ~~this~~Acquired, ~~box~~Disposed ifof, noor ~~longersubject~~Beneficially toOwned ~~Section~~------------------------------------------------------------------------------------------------------------------------------------ ~~16.~~1)Title ~~Form~~of Security 2)Trans- 3.Trans- 4.Securities Acquired(A) 5)Amount of 6) 7)Nature of action action or ~~Form5~~Disposed ~~obligations~~of ~~may~~(D) ~~continue.See~~Securities ~~Instruction~~Indirect 1Date Code A Beneficially D Beneficial (bMonth/ or Owned at or Ownership Day/Year). ~~UNITED~~Code ~~STATES~~V ~~SECURITIES~~Amount ~~AND~~D ~~EXCHANGE~~Price ~~COMMISSIONWashington~~End of Month I ------------------------------------------------------------------------------------------------------------------------------------ Common Stock 09/30/02 A 3,136.0000 DA $3.C985000 14,248.4240 ~~20549STATEMENT~~D OFDirect ~~CHANGES~~Table INII ~~BENEFICIAL~~(PART ~~OWNERSHIPFiled~~1) ~~pursuant~~Derivative toSecurities ~~Section~~Acquired, 16Disposed of, or Beneficially Owned (aColumns 1 through 6) ------------------------------------------------------------------------------------------------------------------------------------ 1)Title of ~~the~~Derivative ~~Securities~~2)Conversion ~~Exchange~~3)Trans- ~~Act~~4)Trans- 5)Number of ~~1934,~~Derivative ~~Section~~6)Date 17Exercisable and Security or Exercise action action Securities Acquired (aA) ofExpiration ~~the~~Date ~~Public~~Price ~~UtilityHolding~~of ~~Company~~Date ~~Act~~Code or Disposed of ~~1935~~(D) orDerivative ~~Section~~Security 30Code V A D Exercisable Expiration ------------------------------------------------------------------------------------------------------------------------------------ Table II (fPART 2) Derivative Securities Acquired, Disposed of, ~~the~~or ~~Investment~~Beneficially ~~Company~~Owned ~~Act~~(Columns 1,3 and 7 through 11) ------------------------------------------------------------------------------------------------------------------------------------ 1)Title of ~~1940~~Derivative ~~OMB~~3)Trans- ~~APPROVALOMB~~7)Title and Amount 8)Price 9)Number: ~~3235~~of 10) 11)Nature of Security action of Underlying of Deri-~~0287Expires:~~ ~~January~~Derivative ~~31,~~Indirect ~~2005Estimated~~Date ~~average~~Securities ~~burdenhours~~vative ~~per~~Securities ~~response.~~D .Beneficial .Amount .or .Security ~~0.5~~Beneficially or Ownership Number of Owned at I - Title Shares End of Month ------------------------------------------------------------------------------------------------------------------------------------ Explanation of Responses:

SIGNATURE OF REPORTING PERSON /S/ By: Sara Henning For: Stanley O. Ikenberry DATE 12/02/02

1. Name and Address of Reporting Person*Ikenberry, Stanley O. (Last) (First) (Middle)Pfizer Inc. Att: Corporate Secretary235 East 42nd Street(Street)New York, NY 10017 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading SymbolPfizer Inc (PFE)3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary) 4. Statement for (Month/Day/Year) June 2002 5. If Amendment, Date of Original (Month/Day/Year) 6. Relationship of Reporting Person(s) to Issuer(Check all applicable) X Director 10% Owner Officer OtherOfficer/OtherDescription 7. Individual or Joint/Group Filing (Check Applicable Line) X Individual Filing Joint/Group Filing

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 3. Transaction Code and Voluntary Code (Instr. 8)Code | V 4. Securities Acquired (A) or Disposed (D) Of (Instr. 3, 4, and 5) Amount | A/D | Price 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Owner- ship Form: Direct(D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

(over)SEC 1474 (3-99)

Ikenberry, Stanley O. - June 2002

Form 4 (continued)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conver- sion or Exercise Price of Deri- vative Security	3. Transaction Date (Month/ Day/ Year)	4. Transaction Code and Voluntary (V) Code (Instr.8)Code \| V	5. Number of Derivative Securities Acquired (A) or Disposed (D) Of (Instr. 3,4 and 5)	6. Date Exercisable(DE) and Expiration Date(ED) (Month/Day/Year) (DE) \| (ED)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr.5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.4)	10.Owner-shipForm ofDeriv-ativeSecurity:Direct(D)orIndirect(I)	11. Nature of Indirect Beneficial Ownership (Instr.4)
Phantom Stock Units	1-for-1	(1)	A \| V	(A) 350	(2) \| (2)	Common Stock - 350	(1)		D
Phantom Stock Units	1-for-1	(3)	A \| V	(A) 387	(2) \| (2)	Common Stock - 387	(3)	130,658	D

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are notrequired to respond unless the form displays a currently valid OMB number. ________________________________ 09-30-2002 ** Signature of Reporting Person DateBy Margaret M. Foran forStanley O. Ikenberry Page 2SEC 1474 (3-99)

Ikenberry, Stanley O. - June 2002

Form 4 (continued)

FOOTNOTE Descriptions for Pfizer Inc (PFE) Form 4 - September 27, 2002 Stanley O. IkenberryPfizer Inc. Att: Corporate Secretary235 East 42nd StreetNew York, NY 10017Explanation of responses: (1) These units were acquired on various dates during the first quarter of 2002 on the basis of prices ranging from $39.74 to $41.25 per unit. (2) These units represent deferred director's compensation (including dividend equivalents thereon) that is settled in cash following the reporting person's retirement from the Board of Directors. (3) These units were acquired on various dates during the second quarter of 2002 on the basis of prices ranging from $35.00 to $39.08 per unit.

Page 3

Filing Compare · IKENBERRY STANLEY